Skip to main content
SpringerLink
Log in

Complications Post Stem Cell Transplantation

  • Chapter
  • First Online:
Basics of Hematopoietic Stem Cell Transplant

  • 464 Accesses

Abstract

Allogeneic stem cell transplant (allo SCT) is a curative treatment for many hematological malignant and non-malignant diseases and provides a long lifespan. Complications occur due to the conditioning of chemotherapy and defects in the immune system. The risk and the type of complications depend on multiple factors including conditioning chemotherapy, the age of the patient, time of allo SCT, the comorbid conditions and other prognostic parameters. Relapse of the underlying primary disease and graft-versus-host disease (GVHD) are leading causes of death, Early complications that occur in the first 100 days of SCT are infections, acute GVHD, engraftment syndrome, hemorrhagic cystitis, sinusoidal obstruction syndrome, thrombotic microangiopathy, and upper respiratory complications. Delayed post-transplant complications occur after day 100 and include cardiovascular, respiratory, nephropathy, chronic GVHD of the liver, liver cirrhosis, hormone imbalances, diabetes, infertility and secondary malignancies. A transplant physician should be aware of the possible complications post-SCT and the management of these complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ghimire S, Weber D, Mavin E, Wang X, Nong, Dickinson AM, Holler E. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol. 2017;8:79.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Krenger W, Blazar BR, Holländer GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011;117(25):6768–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Turner BE, Kambouris ME, Sinfield L, Lange J, Burns AM, Lourie R, et al. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Transplantation. 2008;86(7):968–76.

    Article  PubMed  Google Scholar 

  4. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010;115(19):3861–8.

    Article  CAS  PubMed  Google Scholar 

  5. Vythoulkas D, Tsirigotis P, Griniezaki M, Konstantellos I, Lazana I. Endothelial dysfunction syndromes after allogeneic stem cell transplantation. Cancer. 2023;15(3):680.

    Article  CAS  Google Scholar 

  6. Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Escolar G, et al. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transplant. 2009;15(5):537–46.

    Article  CAS  PubMed  Google Scholar 

  7. Schmid PM, Bouazzaoui A, Doser K, Schmid K, Hoffmann P, Schroeder JA, et al. Endothelial dysfunction and altered mechanical and structural properties of resistance arteries in a murine model of graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(10):1493–500.

    Article  CAS  PubMed  Google Scholar 

  8. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet Lond Engl. 2002;359(9323):2078–83.

    Article  Google Scholar 

  9. Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168(4):481–91.

    Article  PubMed  Google Scholar 

  10. Stavrou E, Lazarus HM. Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr J Hematol Infect Dis. 2010;2(3):e2010033.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Luft T, Dreger P, Radujkovic A. Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation. Bone Marrow Transplant. 2021;56(10):2326–35.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant. 2008;41(8):677–86.

    Article  CAS  PubMed  Google Scholar 

  13. Peña E, Souza CA, Escuissato DL, Gomes MM, Allan D, Tay J, et al. Noninfectious pulmonary complications after hematopoietic stem cell transplantation: practical approach to imaging diagnosis. Radiographics. 2014;34(3):663–83.

    Article  PubMed  Google Scholar 

  14. Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med. 2006;27(3):297–309.

    Article  PubMed  Google Scholar 

  15. Chi AK, Soubani AO, White AC, Miller KB. An update on pulmonary complications of hematopoietic stem cell transplantation. Chest. 2013;144(6):1913–22.

    Article  PubMed  Google Scholar 

  16. Sharma SK, Kumar S, Singh AK, Seth T, Mishra P, Sharma S, et al. Diffuse alveolar hemorrhage following allogeneic peripheral blood stem cell transplantation: a case report and a short review. Indian J Hematol Blood Transfus. 2014;30(1):41–4.

    Article  PubMed  Google Scholar 

  17. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(7):749–59.

    Article  PubMed  Google Scholar 

  18. Au BKC, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1072–8.

    Article  PubMed  Google Scholar 

  19. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9(10):657–66.

    Article  PubMed  Google Scholar 

  20. Diab M, ZazaDitYafawi J, Soubani AO. Major pulmonary complications after hematopoietic stem cell transplant. Exp Clin Transplant. 2016;14(3):259–70.

    PubMed  Google Scholar 

  21. Sharma SK, Kumar S, Singh AK, Seth T, Mishra P, Mahapatra M, et al. Feasibility and outcome of CT-guided lung biopsy in patients with hematological diseases and suspected fungal pneumonia. J Infect Dev Ctries. 2013;7(10):748–52.

    Article  PubMed  Google Scholar 

  22. Soubani AO, Pandya CM. The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2010;3(3):143–57.

    Article  PubMed  Google Scholar 

  23. Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med. 2002;166(5):641–5.

    Article  PubMed  Google Scholar 

  24. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Bone Marrow Transplant. 2006;38(11):765–8.

    Article  CAS  PubMed  Google Scholar 

  25. Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011;183(9):1262–79.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Clark JG, Madtes DK, Martin TR, Hackman RC, Farrand AL, Crawford SW. Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Crit Care Med. 1999;27(9):1800–6.

    Article  CAS  PubMed  Google Scholar 

  27. Bilgrami SF, Metersky ML, McNally D, Naqvi BH, Kapur D, Raible D, et al. Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation. Ann Pharmacother. 2001;35(2):196–201.

    Article  CAS  PubMed  Google Scholar 

  28. Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation. 1997;63(8):1079–86.

    Article  CAS  PubMed  Google Scholar 

  29. Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ, et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant. 2005;11(7):542–50.

    Article  PubMed  Google Scholar 

  30. Gazourian L, Rogers AJ, Ibanga R, Weinhouse GL, Pinto-Plata V, Ritz J, et al. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014;89(4):404–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129(4):448–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, et al. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014;20(6):858–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cordier JF. Cryptogenic organising pneumonia. Eur Respir J. 2006;28(2):422–46.

    Article  PubMed  Google Scholar 

  34. Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518–34.

    Article  PubMed  Google Scholar 

  35. Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. Radiation-induced lung injury: current evidence. BMC Pulm Med. 2021;21(1):9.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Franquet T, Müller NL, Lee KS, Giménez A, Flint JD. High-resolution CT and pathologic findings of noninfectious pulmonary complications after hematopoietic stem cell transplantation. AJR Am J Roentgenol. 2005;184(2):629–37.

    Article  PubMed  Google Scholar 

  37. Forman SJ, Negrin RS, Antin JH, Appelbaum FR. Thomas’ hematopoietic cell transplantation: stem cell transplantation. Hoboken: Wiley; 2015.

    Book  Google Scholar 

  38. Maffini E, Festuccia M, Brunello L, Boccadoro M, Giaccone L, Bruno B. Neurologic complications after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(3):388–97.

    Article  PubMed  Google Scholar 

  39. Saiz A, Graus F. Neurological complications of hematopoietic cell transplantation. Semin Neurol. 2005;23:388–97.

    Google Scholar 

  40. Weber C, Schaper J, Tibussek D, Adams O, Mackenzie CR, Dilloo D, et al. Diagnostic and therapeutic implications of neurological complications following paediatric haematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(3):253–9.

    Article  CAS  PubMed  Google Scholar 

  41. Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transplant. 2015;50(8):1030–6.

    Article  CAS  PubMed  Google Scholar 

  42. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant. 2000;25(6):657–64.

    Article  CAS  PubMed  Google Scholar 

  43. Brown JR, Bharucha T, Breuer J. Encephalitis diagnosis using metagenomics: application of next generation sequencing for undiagnosed cases. J Infect. 2018;76(3):225–40.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Gabriel M, Hoeben BAW, Uhlving HH, Zajac-Spychala O, Lawitschka A, Bresters D, et al. A review of acute and long-term neurological complications following haematopoietic stem cell transplant for paediatric acute lymphoblastic leukaemia. Front Pediatr. 2021;9:774853. https://doi.org/10.3389/fped.2021.774853.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Guermazi A, Gluckman E, Tabti B, Miaux Y. Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol. 2003;13(2):377–88.

    Article  PubMed  Google Scholar 

  46. Mahad DJ, Mahad D, Helldén A, Jarvis J, Mitra D, Gholkar A, et al. Aciclovir induced posterior leucoencephalopathy. J Neurol Neurosurg Psychiatry. 2005;76(9):1308–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Dhar R. Neurologic complications of transplantation. Handb Clin Neurol. 2017;141:545–72.

    Article  CAS  PubMed  Google Scholar 

  48. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007;189(4):904–12.

    Article  PubMed  Google Scholar 

  49. Marcus RE, Goldman JM. Convulsions due to high-dose busulphan. Lancet. 1984;2(8417–8418):1463.

    Article  CAS  PubMed  Google Scholar 

  50. Murphy CP, Harden EA, Thompson JM. Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacother. 1992;26(1):30–1.

    Article  CAS  PubMed  Google Scholar 

  51. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008;28(12):1502–10.

    Article  CAS  PubMed  Google Scholar 

  52. Diaz-Carrasco MS, Olmos R, Blanquer M, Velasco J, Sánchez-Salinas A, Moraleda JM. Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan. Int J Clin Pharm. 2013;35(3):339–43.

    Article  CAS  PubMed  Google Scholar 

  53. Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol. 1990;8(8):1399–401.

    Article  CAS  PubMed  Google Scholar 

  54. Grauer O, Wolff D, Bertz H, Greinix H, Kühl JS, Lawitschka A, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain J Neurol. 2010;133(10):2852–65.

    Article  Google Scholar 

  55. McDonald JW, Goldberg MP, Gwag BJ, Chi SI, Choi DW. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann Neurol. 1996;40(5):750–8.

    Article  CAS  PubMed  Google Scholar 

  56. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13(5):313–26.

    Article  CAS  PubMed  Google Scholar 

  57. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.

    Article  CAS  PubMed  Google Scholar 

  58. Gaziev J, Marziali S, Paciaroni K, Isgrò A, Di Giuliano F, Rossi G, et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(9):1531–40.

    Article  PubMed  Google Scholar 

  59. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427–32.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology. 2005;41(2):345–52.

    Article  CAS  PubMed  Google Scholar 

  62. Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood. 2004;103(1):78–84.

    Article  CAS  PubMed  Google Scholar 

  63. Wong KM, Atenafu EG, Kim D, Kuruvilla J, Lipton JH, Messner H, et al. Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(10):1589–99.

    Article  PubMed  Google Scholar 

  64. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51(4):1450–60.

    Article  PubMed  Google Scholar 

  65. Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res. 2002;11(2):215–29.

    Article  PubMed  Google Scholar 

  66. Deschênes M, Laneuville P. Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection. Hepatology. 2004;39(3):867; author reply 867-868.

    Article  PubMed  Google Scholar 

  67. Peffault de Latour R, Lévy V, Asselah T, Marcellin P, Scieux C, Adès L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103(5):1618–24.

    Article  CAS  PubMed  Google Scholar 

  68. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–68.

    Article  PubMed  Google Scholar 

  69. Sakai M, Strasser SI, Shulman HM, McDonald SJ, Schoch HG, McDonald GB. Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology, and outcome. Bone Marrow Transplant. 2009;44(7):441–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Deeg HJ, Antin JH. The clinical spectrum of acute graft-versus-host disease. Semin Hematol. 2006;43(1):24–31.

    Article  PubMed  Google Scholar 

  71. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology. 1988;8(3):463–70.

    Article  CAS  PubMed  Google Scholar 

  72. Shulman HM, Sullivan KM. Graft-versus-host disease: allo- and autoimmunity after bone marrow transplantation. Concepts Immunopathol. 1988;6:141–65.

    CAS  PubMed  Google Scholar 

  73. Sharma SK. What a clinical hematologist should know about T cells? Int Blood Res Rev. 2020;11:20–32.

    Article  Google Scholar 

  74. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12(1):31–47.

    Article  PubMed  Google Scholar 

  75. Arat M, Idilman R, Soydan EA, Soykan I, Erden E, Karayalçin S, et al. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. Clin Transpl. 2005;19(6):798–803.

    Article  Google Scholar 

  76. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol. 2001;51(5):400–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.

    Article  PubMed  Google Scholar 

  78. Trauner M, Nathanson MH, Rydberg SA, Koeppel TA, Gartung C, Sessa WC, et al. Endotoxin impairs biliary glutathione and HCO3- excretion and blocks the choleretic effect of nitric oxide in rat liver. Hepatology. 1997;25(5):1184–91.

    Article  CAS  PubMed  Google Scholar 

  79. Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374(23):2256–67.

    Article  PubMed  Google Scholar 

  80. Lopes JA, Jorge S, Neves M. Acute kidney injury in HCT: an update. Bone Marrow Transplant. 2016;51(6):755–62.

    Article  CAS  PubMed  Google Scholar 

  81. Hingorani S, Finn LS, Pao E, Lawler R, Schoch G, McDonald GB, et al. Urinary elafin and kidney injury in hematopoietic cell transplant recipients. Clin J Am Soc Nephrol. 2015;10(1):12–20.

    Article  CAS  PubMed  Google Scholar 

  82. Krishnappa V, Gupta M, Manu G, Kwatra S, Owusu OT, Raina R. Acute kidney injury in hematopoietic stem cell transplantation: a review. Int J Nephrol. 2016;2016:5163789.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol. 2011;7(4):189–200.

    Article  CAS  PubMed  Google Scholar 

  84. Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, et al. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17(8):1176–81.

    Article  CAS  PubMed  Google Scholar 

  85. Woo M, Przepiorka D, Ippoliti C, Warkentin D, Khouri I, Fritsche H, et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 1997;20(12):1095–8.

    Article  CAS  PubMed  Google Scholar 

  86. Atkinson K, Biggs JC, Hayes J, Ralston M, Dodds AJ, Concannon AJ, et al. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol. 1983;54(1):59–67.

    Article  CAS  PubMed  Google Scholar 

  87. Ramlal R, Rondon G, Lahoti A, Champlin RE, Alousi AM. Improved renal outcomes in patients converted from tacrolimus to sirolimus after developing acute kidney injury post allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(3):S293–4.

    Article  Google Scholar 

  88. Caliskan Y, Besisik SK, Sargin D, Ecder T. Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2006;38(2):141–7.

    Article  CAS  PubMed  Google Scholar 

  89. Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol. 2006;17(7):1995–2005.

    Article  PubMed  Google Scholar 

  90. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589–600.

    Article  CAS  PubMed  Google Scholar 

  91. Gavriilaki E, Sakellari I. Kidney disease after allogeneic hematopoietic cell transplantation: in search of the truth. Acta Haematol. 2020;143(5):405–6.

    Article  PubMed  Google Scholar 

  92. Sakaguchi M, Nakayama K, Yamaguchi H, Mii A, Shimizu A, Inai K, et al. Risk factors for acute kidney injury and chronic kidney disease following allogeneic hematopoietic stem cell transplantation for hematopoietic malignancies. Acta Haematol. 2020;143(5):452–64.

    Article  PubMed  Google Scholar 

  93. Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14(2):579–85.

    Article  CAS  PubMed  Google Scholar 

  94. Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Čižman B. Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol. 2006;1(4):685–94.

    Article  PubMed  Google Scholar 

  95. Rao PS. Nephrotic syndrome in patients with peripheral blood stem cell transplant. Am J Kidney Dis. 2005;45(4):780–5.

    Article  PubMed  Google Scholar 

  96. Ataca Atilla P, Akkus E, Atilla E, Gokmen N, Civriz Bozdag S, Kurt Yuksel M, et al. Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation. Clin Transpl. 2020;34(10):e14049.

    Article  Google Scholar 

  97. Cattoni A, Molinari S, Gaiero A, Lorenzo PD, Fichera G, Riva B, et al. Thyroid disorders following hematopoietic stem cell transplantation in childhood: impact of conditioning regimen on thyroid dysfunction, volume changes, and occurrence of nodules. Transplant Cell Ther. 2022;28(8):506.

    Article  Google Scholar 

  98. Rovó A, Tichelli A, Passweg JR, Heim D, Meyer-Monard S, Holzgreve W, et al. Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood. 2006;108(3):1100–5.

    Article  PubMed  Google Scholar 

  99. Savani BN, Griffith ML, Jagasia S, Lee SJ. How I treat late effects in adults after allogeneic stem cell transplantation. Blood. 2011;117(11):3002–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Cho WK, Lee JW, Chung NG, Jung MH, Cho B, Suh BK, et al. Primary ovarian dysfunction after hematopoietic stem cell transplantation during childhood: busulfan-based conditioning is a major concern. J Pediatr Endocrinol Metab. 2011;24(11–12):1031–5.

    PubMed  Google Scholar 

  101. Orio F, Muscogiuri G, Palomba S, Serio B, Sessa M, Giudice V, et al. Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells. Sci World J. 2014;2014:e282147.

    Article  Google Scholar 

  102. Chatterjee R, Goldstone AH. Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Bone Marrow Transplant. 1996;17(1):5–11.

    CAS  PubMed  Google Scholar 

  103. Joshi S, Savani B, Chow E, Gilleece M, Halter J, Jacobsohn D, et al. Clinical guide to fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2014;49(4):477–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Li Z, Mewawalla P, Stratton P, Yong ASM, Shaw BE, Hashmi S, et al. Sexual health in hematopoietic stem cell transplant recipients. Cancer. 2015;121(23):4124–31.

    Article  PubMed  Google Scholar 

  105. Fuji S, Rovó A, Ohashi K, Griffith M, Einsele H, Kapp M, et al. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. Bone Marrow Transplant. 2016;51(8):1041–9.

    Article  CAS  PubMed  Google Scholar 

  106. Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, et al. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica. 2015;100(2):284–92.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res. 1999;14(3):342–50.

    Article  CAS  PubMed  Google Scholar 

  108. Schulte CMS, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood. 2004;103(10):3635–43.

    Article  CAS  PubMed  Google Scholar 

  109. Thygesen KH, Schjødt I, Jarden M. The impact of hematopoietic stem cell transplantation on sexuality: a systematic review of the literature. Bone Marrow Transplant. 2012;47(5):716–24.

    Article  CAS  PubMed  Google Scholar 

  110. Anserini P, Chiodi S, Spinelli S, Costa M, Conte N, Copello F, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant. 2002;30(7):447–51.

    Article  CAS  PubMed  Google Scholar 

  111. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Loren AW, Chow E, Jacobsohn DA, Gilleece M, Halter J, Joshi S, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2011;17(2):157–66.

    Article  PubMed  Google Scholar 

  113. Salooja N, Szydlo RM, Socie G, Rio B, Chatterjee R, Ljungman P, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001;358(9278):271–6.

    Article  CAS  PubMed  Google Scholar 

  114. Sanders JE. Growth and development after hematopoietic cell transplant in children. Bone Marrow Transplant. 2008;41(2):223–7.

    Article  CAS  PubMed  Google Scholar 

  115. Papadimitriou A, Urena M, Hamill G, Stanhope R, Leiper AD. Growth hormone treatment of growth failure secondary to total body irradiation and bone marrow transplantation. Arch Dis Child. 1991;66(6):689–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(3):337–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Jadoul P, Donnez J. How does bone marrow transplantation affect ovarian function and fertility? Curr Opin Obstet Gynecol. 2012;24(3):164–71.

    Article  PubMed  Google Scholar 

  118. Vantyghem MC, Cornillon J, Decanter C, Defrance F, Karrouz W, Leroy C, et al. Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Dis. 2014;9:162. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243320/.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Piccioni P, Scirpa P, D’Emilio I, Sora F, Scarciglia M, Laurenti L, et al. Hormonal replacement therapy after stem cell transplantation. Maturitas. 2004;49(4):327–33.

    Article  CAS  PubMed  Google Scholar 

  120. Boulad F, Bromley M, Black P, Heller G, Sarafoglou K, Gillio A, et al. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant. 1995;15(1):71–6.

    CAS  PubMed  Google Scholar 

  121. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927–95.

    Article  PubMed  Google Scholar 

  122. Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau JL, Masszi T, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93(8):1203–10.

    Article  PubMed  Google Scholar 

  123. Baker KS, Ness KK, Steinberger J, Carter A, Francisco L, Burns LJ, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109(4):1765–72.

    Article  CAS  PubMed  Google Scholar 

  124. Risdon G, Gaddy J, Stehman FB, Broxmeyer HE. Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation. Cell Immunol. 1994;154(1):14–24.

    Article  CAS  PubMed  Google Scholar 

  125. Politikos I, Boussiotis VA. The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation. Blood. 2014;124(22):3201–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol. 2008;127(3):286–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 2009;44(8):453–5.

    Article  CAS  PubMed  Google Scholar 

  128. Socié G, Baker KS, Bhatia S. Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(1):139–50.

    Article  Google Scholar 

  129. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989;321(12):784–9.

    Article  CAS  PubMed  Google Scholar 

  130. Danylesko I, Shimoni A. Second malignancies after hematopoietic stem cell transplantation. Curr Treat Options in Oncol. 2018;19(2):9.

    Article  Google Scholar 

  131. Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Peggs KS, Banerjee L, Thomson K, Mackinnon S. Post transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion. Bone Marrow Transplant. 2003;31(8):725–6; author reply 727.

    Article  CAS  PubMed  Google Scholar 

  133. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Burns DM, Rana S, Martin E, Nagra S, Ward J, Osman H, et al. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplant. 2016;51(6):825–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48(4):537–43.

    Article  CAS  PubMed  Google Scholar 

  136. Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 2007;109(6):2643–548.

    Article  CAS  PubMed  Google Scholar 

  137. Marleau AM, Sarvetnick N. T cell homeostasis in tolerance and immunity. J Leukoc Biol. 2005;78(3):575–84.

    Article  CAS  PubMed  Google Scholar 

  138. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program. 2011;2011:280–4.

    Article  PubMed  Google Scholar 

  139. Daikeler T, Tichelli A, Passweg J. Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res. 2012;71(2):439–44.

    Article  CAS  PubMed  Google Scholar 

  140. Kamboj M, Mihu CN, Sepkowitz K, Kernan NA, Papanicolaou GA. Work-up for infectious diarrhea after allogeneic hematopoietic stem cell transplantation: single specimen testing results in cost savings without compromising diagnostic yield. Transpl Infect Dis. 2007;9(4):265–9.

    Article  CAS  PubMed  Google Scholar 

  141. Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation. 2011;92(4):426–32.

    Article  PubMed  Google Scholar 

  142. Borgaonkar MR, Duggan PR, Adams G. Differing clinical manifestations of celiac disease transmitted by bone marrow transplantation. Dig Dis Sci. 2006;51(1):210–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hemato-oncology and Bone Marrow Transplantation, Venkateshwar Hospital, New Delhi, Delhi, India

    Sanjeev Kumar Sharma

Authors
  1. Sanjeev Kumar Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sharma, S.K. (2023). Complications Post Stem Cell Transplantation. In: Basics of Hematopoietic Stem Cell Transplant. Springer, Singapore. https://doi.org/10.1007/978-981-19-5802-1_47

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5802-1_47

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5801-4

  • Online ISBN: 978-981-19-5802-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation